Sight Sciences’ (SGHT) “Overweight” Rating Reiterated at Piper Sandler

Sight Sciences (NASDAQ:SGHT)‘s stock had its “overweight” rating restated by stock analysts at Piper Sandler in a note issued to investors on Thursday, Benzinga reports. They presently have a $12.00 price objective on the stock, up from their prior price objective of $9.00. Piper Sandler‘s price objective would suggest a potential upside of 22.62% from the stock’s previous close.

SGHT has been the topic of a number of other reports. HC Wainwright assumed coverage on shares of Sight Sciences in a research report on Thursday, October 15th. They issued a “buy” rating and a $14.00 price objective on the stock. Citigroup boosted their price target on shares of Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. UBS Group increased their target price on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.62.

Sight Sciences Stock Performance

NASDAQ SGHT traded up $0.11 during trading on Thursday, reaching $9.79. The company’s stock had a trading volume of 315,780 shares, compared to its average volume of 274,853. Sight Sciences has a twelve month low of $3.38 and a twelve month high of $10.14. The firm has a market cap of $539.11 million, a price-to-earnings ratio of -17.55 and a beta of 2.44. The business’s fifty day moving average price is $8.66 and its 200-day moving average price is $6.05. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.67 and a current ratio of 4.95.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%. The firm had revenue of $24.92 million for the quarter, compared to analysts’ expectations of $23.55 million. As a group, analysts anticipate that Sight Sciences will post -0.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CTO David Badawi sold 7,797 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $70,562.85. Following the sale, the chief technology officer owned 1,975,075 shares of the company’s stock, valued at approximately $17,874,428.75. This represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Badawi sold 29,653 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $268,359.65. Following the sale, the chief executive officer owned 6,092,819 shares in the company, valued at approximately $55,140,011.95. This trade represents a 0.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 47,646 shares of company stock valued at $429,157. 30.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sight Sciences

Several hedge funds have recently modified their holdings of SGHT. BlackRock Inc. purchased a new stake in shares of Sight Sciences during the 2nd quarter valued at $16,710,000. GSA Capital Partners LLP acquired a new position in shares of Sight Sciences in the second quarter worth about $908,000. Bank of America Corp DE acquired a new position in shares of Sight Sciences in the 2nd quarter valued at approximately $520,000. Bank of New York Mellon Corp bought a new position in Sight Sciences during the 2nd quarter valued at $495,000. Finally, SCS Capital Management LLC acquired a new position in Sight Sciences during the 2nd quarter worth $488,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Higher revenue outlook: Sight Sciences raised its 2026 revenue guidance to $92–$93 million and indicated a higher target of about $12 million for IDE. The updated outlook signals confidence in growth. Article: Sight Sciences signals 2026 revenue outlook
• Positive Sentiment: Q3 revenue topped estimates: Revenue was $24.92 million, above analysts’ $23.55 million estimate. The quarterly loss of $0.12 per share matched expectations and narrowed from $0.16 a year earlier. Article: Sight Sciences Q3 2026 financial results
• Positive Sentiment: CMS code for TearCare: CMS established a direct practice expense supply code for TearCare’s single-use SmartLids component. This may improve payment recognition and help support use of the product, though the announcement does not specify a payment rate. Article: CMS establishes a TearCare SmartLids supply code
• Negative Sentiment: Profitability remains a concern: SGHT still reported a quarterly loss, so investors will look for revenue growth to translate into improved margins and a path toward profitability.

About Sight Sciences

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.